富祥药业(300497) - 2021 Q1 - 季度财报

Financial Performance - Revenue for Q1 2021 was CNY 395,130,083.80, an increase of 7.60% compared to CNY 367,209,360.78 in the same period last year[9] - Net profit attributable to shareholders decreased by 11.34% to CNY 74,308,610.16 from CNY 83,809,352.55 year-on-year[9] - Net profit excluding non-recurring items fell by 20.19% to CNY 67,242,056.86 compared to CNY 84,250,490.52 in the previous year[9] - Basic earnings per share decreased by 54.84% to CNY 0.14 from CNY 0.31 in the same quarter last year[9] - Net profit for Q1 2021 was CNY 74,164,561.86, compared to CNY 84,111,799.58 in the same period last year, reflecting a decrease of approximately 11.5%[64] - Operating profit for the first quarter was CNY 87,187,456.18, down from CNY 98,607,031.77 year-over-year, reflecting a decline of approximately 11.4%[68] Cash Flow - Net cash flow from operating activities dropped significantly by 56.73% to CNY 36,055,298.94 from CNY 83,325,288.04[9] - Cash inflow from operating activities totaled CNY 235,086,088.28, compared to CNY 273,275,198.73 in the previous year, indicating a decrease of about 14%[70] - The net cash flow from operating activities was CNY 36,055,298.94, significantly lower than CNY 83,325,288.04 in the prior year, representing a decline of approximately 56.7%[71] - The net cash flow from investment activities was -445,402,561.53 CNY, compared to -52,858,660.10 CNY in the previous year, indicating a significant increase in cash outflow[75] - The net cash flow from financing activities was 144,903,229.61 CNY, compared to 108,663,540.35 CNY in the previous year, showing a growth of approximately 33.4%[75] Assets and Liabilities - Total assets increased by 4.79% to CNY 4,239,466,342.96 from CNY 4,045,665,857.13 at the end of the previous year[9] - Total liabilities increased to CNY 1,117,412,633.70 from CNY 997,927,277.88, marking an increase of about 12%[56] - Non-current assets totaled CNY 1,856,308,326.80, up from CNY 1,679,002,030.42, indicating a growth of about 10.6%[55] - The company's equity increased to CNY 3,035,177,132.22 from CNY 2,960,276,693.68, showing growth in shareholder value[60] Shareholder Information - The company reported a total of 34,610 shareholders at the end of the reporting period[13] - The top shareholder, Bao Jianhua, holds 20.88% of the shares, with 90,015,808 shares pledged[13] - The total equity attributable to shareholders reached CNY 3,081,804,679.25, up from CNY 3,007,345,500.94, reflecting an increase of about 2.5%[57] Investments and Projects - The company completed the construction of its first sterile lyophilized raw material drug production facility, which has begun trial production[40] - The new enzyme inhibitor expansion project has a total investment commitment of RMB 35,000 million, with 67.71% of the investment completed by December 31, 2021[46] - The environmental facility upgrade project has a total investment of RMB 7,000 million, with 53.37% completed as of March 1, 2021[46] Operational Challenges - The company faces increased operational pressure due to international trade tensions and rising raw material prices amid stricter domestic environmental regulations[41] - The company aims to maintain stable operations and healthy growth in performance to reward investors and fulfill social responsibilities[41] Research and Development - Research and development expenses increased by 33% as the company intensified its R&D efforts[29] - Research and development expenses increased to CNY 18,910,244.93 from CNY 14,218,726.82, indicating a focus on innovation[63] Other Financial Metrics - Other income increased by 98.96%, mainly due to an increase in government subsidies received[34] - The company received CNY 21,961,930.04 in tax refunds, up from CNY 11,967,997.78 in the previous year, indicating an increase of about 83.4%[70] - The company paid CNY 53,329,438.61 to employees, which is an increase from CNY 41,241,036.33 in the same period last year, reflecting a rise of approximately 29.3%[71] Audit and Compliance - The first quarter report was not audited, which may affect the reliability of the financial data presented[85]